Role of the intestinal microbiome in liver fibrosis development and new treatment strategies.
Journal
Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
05
12
2018
revised:
26
01
2019
accepted:
14
02
2019
pubmed:
12
3
2019
medline:
28
8
2019
entrez:
12
3
2019
Statut:
ppublish
Résumé
Liver cirrhosis is a major cause of morbidity and mortality worldwide. The most common chronic liver diseases in western countries are alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Although these diseases have different causes, liver fibrosis develops via shared mechanisms. The liver and intestinal microbiome are linked by the portal vein and have bidirectional interactions. Changes in the intestinal microbiome contribute to the pathogenesis and progression of liver diseases including ALD, NAFLD, viral hepatitis and cholestatic disorders, based on studies in patients and animal models. Intestinal microbial dysbiosis has been associated with liver cirrhosis and its complications. We review the mechanisms by which alterations in the microbiome contribute to liver fibrosis and discuss microbiome-based treatment approaches.
Identifiants
pubmed: 30853445
pii: S1931-5244(19)30037-4
doi: 10.1016/j.trsl.2019.02.005
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-38Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA020703
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA021856
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026939
Pays : United States
Informations de copyright
Published by Elsevier Inc.